FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894885231> ?p ?o ?g. }

• W2894885231 endingPage "6603" @default.
• W2894885231 startingPage "6599" @default.
• W2894885231 abstract "Hodgkin lymphoma (HL) represents ~11% of all lymphoma cases. This disease occurs in young adults, but also affects people over 55 years of age. Despite the fact that >80% of all newly diagnosed patients under 60 will achieve a sustained complete response (CR), 5%-10% of HL patients are refractory to initial treatment and 10%-30% of patients will eventually relapse after an initial CR. The treatment recommendation for primary refractory or relapsed HL patients is salvage therapy followed by high-dose chemotherapy and autologous stem cell transplantation. Following this approach, a significant part will still relapse at any moment. Thus, further research and new drugs or combinations are required. Overexpression of COX-2 has been associated with poor prognosis in relapse/refractory HL patients, so it could be a potential therapeutic target in HL. For this purpose, several drugs may have a role: specific COX-2 inhibitors such as celecoxib or other anti-inflammatory drugs such as lenalidomide may further inhibit lipopolysaccharide-mediated induction of COX-2. Moreover, lenalidomide and COX-2 inhibitors (celecoxib) have been tested in solid tumors with encouraging results. We present a case of a young female diagnosed with a heavily pretreated HL nodular sclerosis subtype who, after failing six treatment lines, only achieved clinical and radiological CR after six cycles of lenalidomide/celecoxib that resulted in an event-free survival of 22 months. We explain the rationale of using this chemotherapy regimen and our patient follow-up." @default.
• W2894885231 created "2018-10-12" @default.
• W2894885231 creator A5003809364 @default.
• W2894885231 creator A5006074198 @default.
• W2894885231 creator A5017576266 @default.
• W2894885231 creator A5018290227 @default.
• W2894885231 creator A5020337135 @default.
• W2894885231 creator A5023255264 @default.
• W2894885231 creator A5053898670 @default.
• W2894885231 creator A5072348961 @default.
• W2894885231 creator A5081849085 @default.
• W2894885231 creator A5089964057 @default.
• W2894885231 date "2018-10-01" @default.
• W2894885231 modified "2023-09-29" @default.
• W2894885231 title "Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma" @default.
• W2894885231 cites W1925707148 @default.
• W2894885231 cites W2007593071 @default.
• W2894885231 cites W2015534476 @default.
• W2894885231 cites W2017144533 @default.
• W2894885231 cites W2022795689 @default.
• W2894885231 cites W2082270284 @default.
• W2894885231 cites W2097620275 @default.
• W2894885231 cites W2106294189 @default.
• W2894885231 cites W2108151685 @default.
• W2894885231 cites W2130198875 @default.
• W2894885231 cites W2139902230 @default.
• W2894885231 cites W2143953518 @default.
• W2894885231 cites W2145474014 @default.
• W2894885231 cites W2155256323 @default.
• W2894885231 cites W2160014454 @default.
• W2894885231 cites W2166258988 @default.
• W2894885231 cites W2339869876 @default.
• W2894885231 cites W2473498748 @default.
• W2894885231 cites W2515479506 @default.
• W2894885231 cites W2944171047 @default.
• W2894885231 cites W4245503015 @default.
• W2894885231 doi "https://doi.org/10.2147/ott.s175016" @default.
• W2894885231 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6188182" @default.
• W2894885231 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30349293" @default.
• W2894885231 hasPublicationYear "2018" @default.
• W2894885231 type Work @default.
• W2894885231 sameAs 2894885231 @default.
• W2894885231 citedByCount "0" @default.
• W2894885231 crossrefType "journal-article" @default.
• W2894885231 hasAuthorship W2894885231A5003809364 @default.
• W2894885231 hasAuthorship W2894885231A5006074198 @default.
• W2894885231 hasAuthorship W2894885231A5017576266 @default.
• W2894885231 hasAuthorship W2894885231A5018290227 @default.
• W2894885231 hasAuthorship W2894885231A5020337135 @default.
• W2894885231 hasAuthorship W2894885231A5023255264 @default.
• W2894885231 hasAuthorship W2894885231A5053898670 @default.
• W2894885231 hasAuthorship W2894885231A5072348961 @default.
• W2894885231 hasAuthorship W2894885231A5081849085 @default.
• W2894885231 hasAuthorship W2894885231A5089964057 @default.
• W2894885231 hasBestOaLocation W28948852311 @default.
• W2894885231 hasConcept C121332964 @default.
• W2894885231 hasConcept C126322002 @default.
• W2894885231 hasConcept C142424586 @default.
• W2894885231 hasConcept C143998085 @default.
• W2894885231 hasConcept C2776063141 @default.
• W2894885231 hasConcept C2776364478 @default.
• W2894885231 hasConcept C2776467144 @default.
• W2894885231 hasConcept C2776694085 @default.
• W2894885231 hasConcept C2779050716 @default.
• W2894885231 hasConcept C2779338263 @default.
• W2894885231 hasConcept C2780775027 @default.
• W2894885231 hasConcept C2781413609 @default.
• W2894885231 hasConcept C2911091166 @default.
• W2894885231 hasConcept C71924100 @default.
• W2894885231 hasConcept C87355193 @default.
• W2894885231 hasConcept C90924648 @default.
• W2894885231 hasConceptScore W2894885231C121332964 @default.
• W2894885231 hasConceptScore W2894885231C126322002 @default.
• W2894885231 hasConceptScore W2894885231C142424586 @default.
• W2894885231 hasConceptScore W2894885231C143998085 @default.
• W2894885231 hasConceptScore W2894885231C2776063141 @default.
• W2894885231 hasConceptScore W2894885231C2776364478 @default.
• W2894885231 hasConceptScore W2894885231C2776467144 @default.
• W2894885231 hasConceptScore W2894885231C2776694085 @default.
• W2894885231 hasConceptScore W2894885231C2779050716 @default.
• W2894885231 hasConceptScore W2894885231C2779338263 @default.
• W2894885231 hasConceptScore W2894885231C2780775027 @default.
• W2894885231 hasConceptScore W2894885231C2781413609 @default.
• W2894885231 hasConceptScore W2894885231C2911091166 @default.
• W2894885231 hasConceptScore W2894885231C71924100 @default.
• W2894885231 hasConceptScore W2894885231C87355193 @default.
• W2894885231 hasConceptScore W2894885231C90924648 @default.
• W2894885231 hasLocation W28948852311 @default.
• W2894885231 hasLocation W28948852312 @default.
• W2894885231 hasLocation W28948852313 @default.
• W2894885231 hasLocation W28948852314 @default.
• W2894885231 hasLocation W28948852315 @default.
• W2894885231 hasLocation W28948852316 @default.
• W2894885231 hasOpenAccess W2894885231 @default.
• W2894885231 hasPrimaryLocation W28948852311 @default.
• W2894885231 hasRelatedWork W1546170890 @default.
• W2894885231 hasRelatedWork W2033089666 @default.
• W2894885231 hasRelatedWork W2040492280 @default.

• next